Therapeutic regeneration of diseased or damaged myocardium with pluripotent stem (PS) cells depends on the ability to efficiently pre-differentiate PS cells in vitro to specialized endpoints within the coronary vascular and cardiomyocyte lineages. In addition, optimal engraftment of PS-derived cells will likely require the isolation of cells at selected developmental endpoints within these lineages. In addition, effects of factors within the transplanted environment on stem cell behavior must be considered. This Subproject addresses each of these requirements with the objective of utilizing pluripotent human embryonic stem cells (hESCs) to re-muscularize damaged myocardium.
Aim 1 tests the hypothesis that human definitive endoderm (DE) induces cardiomyogenesis in pluripotent hESCs, as well as in adult (c-kit+) stem cells. After optimizing DE-induced differentiation, factors secreted by DE will be proteomically characterized to design a biochemically-defined cardiomyogenic mixture, to be evaluated using a novel luciferase-based screening assay that monitors cardiomyogenesis in hESCs in real-time.
Aim 2 will isolate Nkx-2.5+/aMHC- cells, which are early in the cardiomyogenic lineage, via FACS selection or direct biochemical induction to test the hypothesis that immature 'cardiomyoblasts', in comparison with hESC-derived mature cardiomyocytes, optimally engraft and functionally regenerate infarcted myocardium. The availability of pure Nkx-2.5+/aMHC- cells (Aim 2) and mature cardiomyocytes (Aim 1) will also enable the genetic profiling of cardiomyogenic transcriptomes, which will further inform cardiomyogenic signaling and consequently growth factor application to optimally induce differentiation.
Aim 3 will assess the effects of growth factors/cytokines in myocardial interstitial fluid (MIF), a non-cellular exudate isolated from ischemic myocardium, on the behavior of hESC-derived cells in the cardiomyogenic lineage. Findings from this study will significantly contribute toward elucidation of how human heart disease may be ameliorated by via cellular therapy.
|Garitaonandia, Ibon; Amir, Hadar; Boscolo, Francesca Sesillo et al. (2015) Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions. PLoS One 10:e0118307|
|Kolander, Kurt D; Holtz, Mary L; Cossette, Stephanie M et al. (2014) Epicardial GATA factors regulate early coronary vascular plexus formation. Dev Biol 386:204-15|
|Lakshmikanthan, Sribalaji; Zieba, Bartosz J; Ge, Zhi-Dong et al. (2014) Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arterioscler Thromb Vasc Biol 34:1486-94|
|Mallanna, Sunil K; Duncan, Stephen A (2013) Differentiation of hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol 26:Unit 1G.4.|
|Sepac, Ana; Si-Tayeb, Karim; Sedlic, Filip et al. (2012) Comparison of cardiomyogenic potential among human ESC and iPSC lines. Cell Transplant 21:2523-30|
|Gundry, Rebekah L; Riordon, Daniel R; Tarasova, Yelena et al. (2012) A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells. Mol Cell Proteomics 11:303-16|
|Van Orman, Jordan R; Si-Tayeb, Karim; Duncan, Stephen A et al. (2012) Induction of cardiomyogenesis in human embryonic stem cells by human embryonic stem cell-derived definitive endoderm. Stem Cells Dev 21:987-94|
|Fisher, Joseph B; Kim, Min-Su; Blinka, Steven et al. (2012) Stress-induced cell-cycle activation in Tip60 haploinsufficient adult cardiomyocytes. PLoS One 7:e31569|
|Cayo, Max A; Cai, Jun; DeLaForest, Ann et al. (2012) JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 56:2163-71|
|Auchampach, John A; Maas, Jason E; Wan, Tina C et al. (2011) Are we putting too much stock in mice? J Mol Cell Cardiol 50:584-5|
Showing the most recent 10 out of 13 publications